Munich / Morristown, NJ – September 10, 2008 – Definiens, the number one Enterprise Image Intelligence™ company, has placed 1st in the 2008 Liver Tumor Segmentation Grand Challenge’s live contest, organized by the International Society of Medical Image Computing and Computer-Assisted Interventions (MICCAI). Against a field of the world’s leading research groups in the area of liver lesion segmentation, Definiens’ fully-automated application outperformed all other methods, including the interactive ones, and received the live competition’s highest scores.
Definiens’ applications accurately and consistently identified and segmented liver lesions in a series of computed tomography (CT) images from various patients. Overall, the Grand Challenge compared the brain lesion, coronary tracking and liver lesion segmentation techniques of 36 industry and academic teams. The performance of the liver lesion segmentation methods was evaluated using a set of comprehensive measures, including tumor surface area and volume.
Definiens’ fully automated liver segmentation application was able to correctly and consistently identify and segment 30 liver lesions representing a range of patients and pathologies. The automatic analysis was compared against manual segmentations performed by several experienced radiologists. The success of the Definiens team in the competition followed an impressive third placing in the fully automated category of the MICCAI Segmentation of the Liver Competition 2007 (SLIVER07). Successive victories in the challenging MICCAI contests provides further validation for Definiens’ pioneering semi- and fully-automated computer-aided detection (CAD) applications.
“It is always a boost to receive clinical and scientific recognition for our exciting work in automated image analysis and our strong finish speaks to the innovation behind Definiens’ technology,” said Frank P. Klein, VP of Medical Imaging at Definiens. “We are currently developing CAD applications for a variety of challenging cancer targets, including lung, liver and lymph nodes.”
A dramatic rise in the volume of digital images to be analyzed has accompanied the increasingly prevalent use of advanced medical imaging systems in cancer diagnostics. Automated CAD applications can assist in overcoming the logistical bottlenecks that are created by a shortage of clinical radiologists, and support healthcare providers in offering patients earlier, more accurate detection and treatment.
Definiens’ CAD applications employ contextual information to identify lesions and tumors smaller than the human eye can detect. The company’s first commercially available CAD application will be released to European customers in early 2009, and will subsequently be submitted for FDA approval for the United States market.
By automating image analysis, Definiens supports Healthcare providers in analyzing and interpreting vast numbers of digital images accurately and consistently. Definiens improves the analysis of tissue samples and non-invasive imaging, enabling translational medicine--from early diagnosis to personalized treatment.
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel Laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Medical, Life Science, and Earth Science markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices in the United States. Further information is available at www.definiens.com.
Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.
| Definiens Eva Tietz Manager Corporate Communications etietz@definiens.com |
Ricochet Public Relations Garry Clark gclark@ricochetpr.com Phone: +1 212 679 3300 114 |